Preliminary Program: Sunday, May 20
8 a.m.-Noon
CME Courses 14-19
8 a.m.-11 a.m.
Industry-Supported Symposia
IS8. The Ongoing Debate Surrounding Atypicals: Are the Benefits Worth the Risks?Supported by Solvay Pharmaceuticals and Wyeth Pharmaceuticals
Balancing Between Efficacy and Side Effects Samuel J. Keith, M.D. | |||||
The Ongoing Debate Surrounding Atypicals: Do the Benefits Outweigh the Risks? Henry A. Nasrallah, M.D. | |||||
The Risk/Benefit Ratio of Atypical Antipsychotics in Early Phase Schizophrenia Elizabeth Bromley, M.D. | |||||
New Mechanisms and Pharmacological Strategies Stephen R. Marder, M.D. | |||||
IS9. Still Sleepy After All These Cures: Hypersomnia in PsychiatrySupported by Cephalon Inc.
The Neurobiology of Hypersomnia Stephen M. Stahl, M.D., Ph.D. | |||||
The Clinical Spectrum of Hypersomnia Daniel J. Buysse, M.D. | |||||
Measurement of Hypersomnia Meeta Singh, M.D. | |||||
Strategies for the Management of Hypersomnia Leslie P. Lundt, M.D. | |||||
Prevalence and Consequences of Hypersomnia Christoper L. Drake, Ph.D. | |||||
IS10. Deconstructing Attention and Cognition in ADHD: New Understandings for Improved ManagementSupported by McNeil Pediatrics
Overview of ADHD Thomas J. Spencer, M.D. | |||||
Neurocircuitry in ADHD Francisco Xavier Castellanos, M.D. | |||||
Pharmacological Treatment of ADHD: Focus on Attention Timothy E. Wilens, M.D. | |||||
Neuropsychology in ADHD Larry J. Seidman, Ph.D. | |||||
Understanding Cognitive and Behavioral Approaches to Treating ADHD in Adults Steven A. Safren, Ph.D. | |||||
IS11. Long-Term Treatment Approaches for Schizophrenia: Comparing Maintenance and Recovery ModelsSupported by Bristol-Myers Squibb Co.
Maintenance and Recovery in Schizophrenia Stephen R. Marder, M.D. | |||||
To Be Announced Peter F. Buckley, M.D. | |||||
To Be Announced Peter Weiden, M.D. | |||||
Adherence With Pharmacotherapy in Schizophrenia and Cognitive-Behavior Therapy Shanaya Rathod, M.D. | |||||
IS12. Dark Horizons: Depression and Cognitive ImpairmentSupported by Forest Laboratories Inc.
To Be Announced Richard Mayeux, M.D. | |||||
The Biology of Depression and Dementia Gary W. Small, M.D. | |||||
Vascular Depression and Vascular Dementia K.R. Krishnan, M.D. | |||||
Mild Cognitive Impairment and Conversion to Alzheimer's Disease Davangere P. Devanand, M.D. | |||||
The Course of Treatment of Patients With Depression and Mild Cognitive Impairment Roy H. Hamilton, M.D. | |||||
9 a.m.-4 p.m.
CME Courses 20-25
1 p.m.-5 p.m.
CME Courses 26-32
1:30 p.m.-4:30 p.m.
Industry-Supported Symposia
IS13. Planning for Success in Schizophrenia ManagementSupported by Janssen Pharmaceutica and Research Foundation
Why Do Patients With Schizophrenia Take Their Medication? Adherence Models for First-Episode Patients Peter J. Weiden, M.D. | |||||
Schizophrenia Treatment Planning: Guidelines, Medication Algorithms, Psychosocial Strategies Dawn I. Velligan, Ph.D. | |||||
Strategies for Assessing and Managing Adherence Dilip V. Jeste, M.D. | |||||
IS14. Making Every Sheep Count: Evidence-Based Approaches to Treating InsomniaSupported by Takeda Pharmaceuticals North America Inc.
The Clinical Neuroscience of Sleep and Insomnia Daniel J. Buysse, M.D. | |||||
Comorbidity Between Insomnia and Psychiatric Illness Meera Narasimhan, M.D. | |||||
Novel Pharmacological Targets for the Management of Insomnia Ruth M. Benca, M.D. | |||||
Innovative Behavioral Approaches for Treating Insomnia and Comorbid Psychiatric Illness Karl Doghramji, M.D. | |||||
IS15. Rethinking Bipolar Disorder: Implications of ComorbiditiesSupported by AstraZeneca Pharmaceuticals
Medical Comorbidities With Bipolar Disorder Gary S. Sachs, M.D. | |||||
Comorbid Substance Abuse in Bipolar Disorder Michael J. Ostacher, M.D. | |||||
Suicidality as a Component of Bipolar Disorder Lauren Marangell, M.D. | |||||
Posttraumatic Stress Disorder and Bipolar Disorder: Critical Overlaps and Possible Links in Pathology and Treatment Lori L. Davis, M.D. | |||||
Neuroimaging of Dual Diagnoses Stephen M. Strakowski, M.D. | |||||
IS16. Caring for Our Most Challenging Patients With Depression: An Interactive Forum on Novel TreatmentsSupported by Cyberonics Inc.
Mechanism of Action of Vagus Nerve Stimulation Charles B. Nemeroff, M.D. | |||||
Efficacy of Repetitive Transcranial Magnetic Stimulation and Magnetic Seizure Therapy Thomas Schlaepfer, M.D. | |||||
Assessing the Efficacy of Vagus Nerve Stimulation in Patients With Treatment Resistant Depression James M. Martinez, M.D. | |||||
Mechanism of Action and Efficacy of Deep Brain Stimulation Helen Mayberg, M.D. | |||||
2:30 p.m.-4 p.m.
Lecture
L1.Carl P. Malmquist, M.D., AAPL/APA's Manfred S. Guttmacher Award Lecture
7 p.m.-10 p.m.
Industry-Supported Symposia
IS17. How Comorbid Is ADHD? Results From Epidemiological and Clinical StudiesSupported by Shire U.S. Inc.
Patterns of Comorbidity in a Longitudinal Sample of Boys and Girls With ADHD Joseph Biederman, M.D. | |||||
Patterns of Comorbidity in a Clinical Sample of Adults With ADHD Thomas J. Spencer, M.D. | |||||
Patterns of Comorbidity in a Community Sample of Adults With ADHD: Results From the National Comorbidity Survey Ronald C. Kessler, Ph.D. | |||||
Morphometric Findings in Adults With ADHD With and Without Comorbid Bipolar Disorder Mike Monuteaux, Sc.D. | |||||
Spectroscopic Findings in Children and Comorbid Bipolar Disorder Perry F. Renshaw, M.D. | |||||
IS18. The Alcohol-Dependent Patient: Improving Outcomes Through AdherenceSupported by Cephalon Inc.
Patient Adherence in the Treatment of Alcohol Dependence: Improving the Journey Toward Abstinence Helen Pettinati, Ph.D. | |||||
Selecting Pharmacotherapies to Improve Patient Adherence Robert M. Swift, M.D., Ph.D. | |||||
To Be Announced Carlo DiClemente, Ph.D. | |||||
Implementing Adherence-Enhancing Strategies in Clinical Practice With Alcohol-Dependent Patients Shimi Kang, M.D. | |||||
IS19. Weighing the Risks and Benefits of Atypical Antipsychotics: Can We Have Our Cake and Eat It Too?Supported by Bristol-Myers Squibb Co.
High Morbidity and Mortality in Schizophrenia and Bipolar Disorder: What, Why, and How? Quinton E. Moss, M.D. | |||||
Metabolic Complications in the Context of Antipsychotic Effectiveness: Lessons From the CATIE Schizophrenia Trial Donald C. Goff, M.D. | |||||
The Dual Health Jeopardy in Schizophrenia: Highly Prevalent Metabolic Disorders and Low Access to Medical Treatment Henry A. Nasrallah, M.D. | |||||
Managing Metabolic Complications During Antipsychotic Therapy: Lessons From ATP III, the ADA, and the APA Workgroup on Antipsychotics and Metabolic Risk John W. Newcomer, M.D. | |||||
Patient, Provider and System-Level Approaches to Reducing Risk of Poor Health Outcomes Lisa Dixon, M.D. | |||||
IS20. STAR*D Findings: Implications for Patients, Clinicians, and Other StakeholdersSupported by Forest Laboratories Inc.
Clinical Methods and Procedures to Enhance Acute and Long-Term Outcomes Junius J. Gonzales, M.D. | |||||
STAR*D: Selecting Among First- and Second-Step Acute Treatments Marlene P. Freeman, M.D. | |||||
STAR*D: Treatments After the First Two Steps, Including Follow-Up A. John Rush, M.D. | |||||
The Role of Other Treatment Options in Managing Depression K. Ranga Krishnan, M.D. ▪ | |||||
